



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Nicoletta ALMIRANTE et al.

**ATTN: Application Branch** 

Application No.: 10/566,292

Attorney Dkt. No.: 026220-00073

Filed: January 27, 2006

For: NITROOXY DERIVATIVES OF LOSARTAN, VALSARTAN,

> CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF

CARDIOVASCULAR DISEASES

# REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Date: November 30, 2006

Sir:

A corrected filing receipt is hereby requested in view of the errors that appear in the original filing receipt. For the convenience of the Patent and Trademark Office, attached are a photocopy of the original filing receipt on which the errors have been noted in red and a copy of the executed Declaration.

Please charge any deficiency or credit any overpayment with respect to this paper to Deposit Account No. 01-2300.

Respectfully submitted,

Schoenhard Registration No. 46512

Customer Number: 004372

ARENT FOX PLLC

1050 Connecticut Avenue, N.W.,

Suite 400

Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

ALS/tss



# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS 1450 ia Virginia 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/566,292	01/27/2006	1614	1640	026220-00073		14	3

**CONFIRMATION NO. 1937** 

**FILING RECEIPT** 

\*OC000000020200166\*

4372 **ARENT FOX PLLC** 1050 CONNECTICUT AVENUE, N.W. SUITE 400 WASHINGTON, DC 20036

Date Mailed: 08/28/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Nicoletta Almirante, Milano, ITALY; Piero Del Soldato, Monza (Milano), ITALY: Ennio Ongini, Segrate (Milano), ITALY;

Power of Attorney: The patent practitioners associated with Customer Number 4372.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/51550 07/20/2004

## Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 03102379.9 07/31/2003 If Required, Foreign Filing License Granted: 08/25/2006

The country code and number of your priority application, to be used for filing abroad under the Paris **Convention, is US10/566.292** 

**Projected Publication Date: 12/07/2006** 

Non-Publication Request: No

Early Publication Request: No

Title

NETROOXY

VALSARTAN

Nitoroxy derivatives of losartan valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases

**Preliminary Class** 

514

# PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

ARENT FOX PLLC

# **Declaration and Power of** for U.S. Patent Application

As a below named inventor, I hereby declare that:

As a below named inventor, I nereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter, which is claimed and for which a patent is sought on the invention entitled

NITROOXY DERIVATIVES OF LOSARTAN, VALSARTAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

	Number and wa			As PCT International	Application
			was amended on		
	nber	and	was amended on	As U.S. Patent Appli	cation
•					
cnowledge reby clain ficate, or w and hav	the duty to disclose in foreign priority bene \$365(a) of any PCT	nformation which is a efits under 35 U.S.C International applica	material to patentab . §119(a)-(d) or §1 tion which designa	ility as defined in 37 C.	n, including the claim(s), as amendal F.R. §1.56. application(s) for patent or inventor y other than the United States, liste PCT International Application having
	03102379.9	EP	21/0	1/2002	Priority Claimed
· · · ·		(Country)		7/2003 /Month/Year Filed)	🛛 Yes 🗌 No
	(Number)		(24)	month real ricu,	
reign		(Country)			☐ Yes ☐ No
oreign	(Number)	(Country)		/Month/Year Filed)	Yes  No
reign plications)	(Number)	(Country)	(Day	/Month/Year Filed) /Month/Year Filed) visional application(s) I	Yes No
oreign oplications)	(Number)	(Country) (Country)  J.S.C. \$119(e) of an	(Day	Month/Year Filed)	Yes No
oreign oplications)	(Number)  (Number)  the benefit under 35 L	(Country) (Country)  J.S.C. \$119(e) of an	(Day (Day, y United States pro	/Month/Year Filed) visional application(s) I  Date)	Yes No
List prior oreign pplications) reby claim	(Number)  (Number)  the benefit under 35 to the depolication In th	(Country) (Country)  J.S.C. §119(e) of an Number)  Number)	(Day, (Day, y United States pro (Filing I	/Month/Year Filed) visional application(s) I  Date)	Yes No
reby claim gnating the oto disclose of the prio	(Number)  (Number)  the benefit under 35 L  (Application I)  (Application I)  See  the benefit under 35 L  United States of Ame	(Country)  (Country)  J.S.C. \$119(e) of an Number)  Number)  attached list for add  J.S.C. \$120 of any perical listed below an U.S. or PCT) in the material to patents below to the country of the patents of the patent	(Day)  y United States pro  (Filing I)  (Filing I)  (Filing I)  (United States applied, insofar as the summer provided by	Month/Year Filed) visional application(s) I  Date)  or provisional applicat  cation(s) or \$365(c) of bject matter of each of the first paragraph of	Yes No
eby claim nating the osed in the to disclose of the prior rior U.S. ations or	(Number)  (Number)  the benefit under 35 L  (Application I  (Application I  United States of American application(s) (to information which is	(Country)  (Country)  (Country)  J.S.C. \$119(e) of an	(Day) (Day) (Day) y United States pro (Filing I (Filing I) (Filing	Month/Year Filed) visional application(s) I Date)  Oate) or provisional applicat cation(s) or \$365(c) of bject matter of each of the first paragraph of 7 C.F.R. \$1.56 which of this application.	isted below.  ions.  any PCT International application(so the claims of this application is no 35, U.S.C. §112, I acknowledge the became available between the filing.
eby claim nating the sed in the to disclose of the prio	(Number)  (Number)  the benefit under 35 U  (Application I)  (Application I)  (See  the benefit under 35 U  United States of Ame eprior application(s) (tell e information which is or application and the n	(Country)  (Country)  J.S.C. \$119(e) of an Number)  Number)  attached list for add  J.S.C. \$120 of any erica listed below an J.S. or PCT) in the material to patentab ational or PCT Intererial No.)	(Day)  y United States pro  (Filing I)  (Filing I)  (Filing I)  (United States applied, insofar as the summer provided by	VMonth/Year Filed) visional application(s) I  Date)  Oate)  or provisional applicat cation(s) or \$365(c) of bject matter of each of the first paragraph of 7 C.F.R. \$1.56 which of this application.  (Status)	isted below.  ions.  any PCT International application(s the claims of this application is no

Please direct all communications to the following address:

Customer No. 004372 ARENT FOX PLLC

1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339 Telephone No. (202) 857-6000; Facsimile No. (202) 638-4810

# BEST AVAILABLE COPY

Page 2

The undersigned hereby authorizes the U.S. attorneys named herein to accept and follow instructions from the undersigned's assignee, if any, and/or, if the undersigned is not a resident of the United States, the undersigned's domestic attorney, patent attorney or patent agent, as to any action to be take in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the U.S.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sale as for.

Nicoletta ALMIRANTE	
Inventor's signature \underset	Secenter 22 2005
Residence Milano, Italy	Date
Citizenship Italian	
Post Office Address Via Caracciolo 26, 20155 Milano, Italy	
Full name of second inventor Piero DEL SOLDATO	
Inventor's signature de de MW	September 7, 2006
Residence Monza (Milano), Italy	Date
Citizenship Italian	
Post Office Address Via E. Toti 22, 20052 Monza (Milano), Italy	
(	
Full name of third inventor Ennio ONGINI	
Inventor's signature Tuelly	Securber 22 2005
Residence Segrate (Milano), Italy	Date
Citizenship Italian	
Post Office Address Via Fratelli Cervi, Residenza Campo, 20090 Segrate (Milano), Italy	
taloni cervi, residenza Campo, 20090 segrate (Milano), Italy	
Full name of fourth inventor	
Inventor's signature	
Residence	Date
Citizenship	
Post Office Address	
Full name of fifth inventor	
Inventor's signature	-
Residence	Date
Citizenship	
Post Office Address	
Full name of sixth investor	
Full name of sixth inventor	
Inventor's signature	Date
Residence	Date
Citizenship	
Post Office Address	